MannKind (MNKD) Q2 FY26 earnings call

MannKind delivered on its three key catalysts for 2026, including the successful launch of Afrezza in pediatrics and the FDA approval of Furoscix ReadyFlow, which is expected to drive significant growth in marketed products. The company also reported positive Phase Ib data for nintedanib DPI, validating its pipeline. While investments in launches and development led to a net loss this quarter, management remains focused on disciplined execution and leveraging these new opportunities for future growth.